Pharmaceutical group Shire and Teva Pharmaceuticals USA have settled litigation concerning Shire's supply of a generic version of Adderall XR.
Shire has been supplying Teva with authorised generic Adderall XR since April 1 but its ability to supply the product was limited by US Drug Enforcement Administration restrictions on amphetamine, the product's active ingredient.
Teva filed suit claiming Shire was in breach of its supply contract. The DEA then granted Shire an additional quota for 2009, allowing it to supply Teva.
Teva has now dismissed its lawsuit, including its claim for damages. No consideration was exchanged as part of the settlement.
Story provided by Business Financial Newswire
Pharmaceutical Process Equipment
